Modified human growth hormone formulations with an increased serum half-life
US8178494B2 · kind B2 · utility
18Cited by
163References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 25, 2007 |
| Grant date | May 15, 2012 |
| Priority date | — |
| Expiry date | Oct 25, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/19
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Formulations of modified growth hormone polypeptides are provided, including human growth hormone polypeptides with one or more non-naturally encoded amino acids with an increased half-life.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.